MedTrace Logo

Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus

NCT00222807 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2017-08-28

No results posted yet for this study

Summary

This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls.

Regardless the treatment status, we collect the same neuroendocrine-immune data on the participants after 2 months.

Conditions

Sponsors & Collaborators

  • American Association for Geriatric Psychiatry

    collaborator OTHER

  • Janssen Pharmaceuticals

    collaborator INDUSTRY

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Ripu D Jindal, MD · University of Pittsburgh

Eligibility

Min Age
14 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00222807 on ClinicalTrials.gov